We’re celebrating a milestone: Glyscend was founded 10 years ago this week!
We are proud of the journey we’ve taken to turn an idea into a Phase 2 clinical-stage drug candidate, and we look forward to many more exciting years of progress ahead.
38
Phase 2 clinical trial underway at five sites across the US! Study to assess weight-loss and evaluate safety and tolerability of GLY-200 after 16-weeks oral treatment in a non-diabetic obese population. Results expected 1Q2025.
#glyscend #obesity #t2diabetes #bio2024
32
Glyscend is honored to have been nominated by the Maryland Tech Council as a 2024 ICON Award finalist for Emerging Life Sciences Company of the Year.
lnkd.in/gVsXtG4s
#t2d #biopharma #lifescience
25
The Glyscend team is looking forward to attending ObesityWeek 2023 hosted by The Obesity Society from October 14 to 17 in Dallas, TX! Join us as we present 3 abstracts highlighting our clinical and preclinical progress with our lead program for #obesity and #t2diabetes.
70
Our team welcomes Sapan Shah, PhD, as CEO. With 25+ years of experience leading innovative #lifescience companies, Dr. Shah is ready and well-equipped to guide Glyscend in its next stage of growth as it advances lead product candidate GLY-200 for #obesity and #type2diabetes.
59
We’re gearing up for #ADA2023 where we look forward to sharing more on our latest progress in the clinic with GLY-200 for the treatment of #T2D and #obesity!
In the meantime, learn more about our completed Phase 2a clinical study via Endpoints News.
lnkd.in/eEwMa2Kd
2
41
Check out this article from @biospace about our positive topline Phase 2a data for GLY-200, a first-in-class polymer drug, in people with Type 2 #Diabetes and #Obesity.
Replying to @glyscend
@glyscend Therapeutics’ lead candidate GLY-200 demonstrated promising safety and efficacy in patients with Type 2 diabetes.
#GlyscendTherapeutics #LifeSciences BioSpace
hubs.li/Q01RPxYZ0
1
28
We are excited to share positive topline results from our Phase 2a clinical trial. Data show the novel mechanism of GLY-200 offers significant reductions in postprandial glucose and body weight in people with type 2 #diabetes. Hear about our Ph 1 data at the 83rd @AmDiabetesAssn
Glyscend is proud to announce the issuance of 4 US Patents (US 11,484,548, 11,491,182, 11,491,183, and 11,576,928) establishing further intellectual property coverage for a class of mucus complexing polymers (MCPs) to treat type 2 #diabetes.
1
41
Check out our one-page feature in the December 2022 issue of Nature's Biopharma Dealmakers to learn more about Glyscend’s unique therapeutic approach to treating type 2 #diabetes and #obesity. nature.com/articles/d43747-0…
Glyscend will be presenting results from our Phase 1 study at ObesityWeek®. Come hear about our oral T2D drug candidate designed to replicate many of the effects of bariatric surgery through pharmacological duodenal exclusion. #OW2022 presentation this Wed, Nov 2nd at 4:45pm PST.
2
A new approach to an old disease! Check out Glyscend's one-page feature in the June'22 issue of Nature's Biopharma Dealmakers.
nature.com/articles/d43747-0…
Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment
businesswire.com/news/home/2…











